[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100520255":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":47,"collaborators":24,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":24,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":24,"enrollmentInfo":59,"targetDuration":24,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":24,"overallStatus":70,"whyStopped":24,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1: BRAF V600 mutation","EXPERIMENTAL","Dabrafenib + Trametinib",[13],"Drug: Dabrafenib + Trametinib",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2: MET ex14 skip mutation","Capmatinib",[18],"Drug: Capmatinib",[20,25],{"type":21,"name":11,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Dabrafenib 150mg BID + Trametinib 2mg QD\u002F（2 cycles）",[9],null,{"type":21,"name":16,"description":26,"armGroupLabels":27,"otherNames":24},"Capmatinib 400mg BID\u002F（2 cycles）",[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":24,"email":33},"Li Zhang, MD","CONTACT","86-20-87343458","zhangli6@mail.sysu.edu.cn",[35],{"facility":36,"status":24,"city":37,"state":38,"zip":24,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":24},"Cancer Center of Sun-Yat Sen University","Guangzhou","Guangdong","China","CN",{"type":42,"coordinates":43},"Point",[44,45],113.25,23.11667,{"lat":45,"lon":44},{"type":48,"investigatorFullName":30,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Director","100520255","phase-2-neoadjuvant-and-adjuvant-targeted-treatment-in-nsclc-with-braf-v600-or-met-exon-14-mutations-100520255",false,"NCT06054191","Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations","A Phase II, Two Parallel Group Study of Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations","Inclusion Criteria:\n\n* 18 years or older.\n* Histologically or cytologically diagnosed stage IB-IIIA and selected IIIB (T3N2, T4N2) NSCLC.\n* Presence of BRAF V600 mutation or METex14 skip mutation in tumor (by PCR or NGS) or blood (by NGS) (pre-treatment biopsy confirmed) in local or other Clinical Laboratory Improvement Amendments (CLIA)-certified lab.\n* Patients whose pre-surgical lesion is measurable, Eligible for surgical resection and scheduled for surgery within 2 weeks after the last does of neoadjuvant treatment.\n* ECOG performance-status score of 0 or 1.\n* No previous anticancer therapy.\n* Patients with stage II or higher non-small-cell lung cancer (NSCLC) and those with suspected brain metastases should have brain imaging (CT or MRI) prior to enrollment to exclude brain metastasis.\n* Could provide pretreatment tumor samples available for biomarker analysis. The subject should have good compliance, who would participate in the research voluntarily, and sign the informed consent.\n\nExclusion Criteria:\n\n* Patients with unresectable (regardless of stage) or metastatic disease (stage IV) or brain metastases.\n* Contain neuroendocrine carcinoma tumor histology.\n* Major surgery within 4 weeks before enrollment, or who have not recovered from side effects of related procedures.\n* History of current interstitial lung disease or pneumonitis.\n* Patients with conditions requiring systemic corticosteroids (\\>10 mg daily prednisone or equivalent) or immunosuppressive medication within 14 days of the first dose of study drug (Inhaled or topical steroids and adrenal-replacement steroids are allowed).\n* History of other malignancies within 5 years (excluding basal cell carcinoma of the skin or other carcinoma in situ that has been resected).\n* Pregnant or lactating women.\n* Those who are allergic to the research drug or its components.\n* Subjects who are deemed unable to comply with the study requirements or complete the study.\n* Those with acquired immunodeficiency syndrome, or any uncontrolled medical disorder, or insufficient function of bone marrow or other important organs.","ALL","18 Years",{"count":60,"type":61},40,"ESTIMATED","INTERVENTIONAL",[64],"PHASE2","This is a Phase II, two parallel group study assessing the efficacy and safety of neoadjuvant and adjuvant targeted therapy in patients with stage IB-IIIA NSCLC harboring BRAF V600 or MET exon14 mutations.",[67,68,69],"NSCLC","BRAF V600 Mutation","MET Exon 14 Mutation","NOT_YET_RECRUITING","2023-10-07",{"date":73,"type":74},"2023-10-10","ACTUAL",{"date":76,"type":61},"2024-02-01",{"date":78,"type":61},"2027-03-01",{"name":5,"class":6},1]